

**IN THE CLAIMS:**

Amend the claims as follows:

Claim 1-75. (Canceled)

Claims 76-105 (Canceled)

106. (Currently Amended) A method of identifying a compound as a putative anti-prostate cancer or anti-breast cancer agent, the method comprising:

determining the expression of a plexinB1 nucleic acid in a cell or cell lysate in the presence of a test compound as compared with expression of the plexinB1 nucleic acid in the cell or the cell lysate in the absence of the test compound,

wherein said plexinB1 nucleic acid comprises the plexinB1 coding sequence of AB007867.1 (SEQ ID NO:112) with at least one mutation mutations in the coding region of the nucleic acid selected from the group consisting of C5059T, C5060T, G5074A, A5107G, A5359G, T5401A, G5452A, G5458A, C5468T, A5474G, A5596G, A5653G, C5662T, A5674G, C5713T, T5714C and C5980T at one or more sites selected from the group consisting of positions 5059, 5060, 5074, 5107, 5359, 5401, 5452, 5458, 5468, 5474, 5596, 5653, 5662, 5674, 5713, 5714, and 5980, and;

wherein a reduction in expression of the plexinB1 nucleic acid in the cell or cell lysate in the presence of the test compound as compared with expression of the plexinB1 nucleic acid in the cell or the cell lysate in the absence of the test compound identifies the test compound as a putative anti-prostate cancer or anti-breast cancer agentthe cancer is prostate or breast cancer.

Claims 107-108. (Canceled)

WILLIAMSON ET AL  
Appl. No. 10/536,804  
Atty. Ref.: 620-373  
Amendment After Final Rejection  
December 21, 2009

109. (Currently Amended) The [[A]] method according to claim 106, wherein said mutations are selected from the group consisting of C5059T, C5060T, G5074A, A5359G, T5401A, G5452A, G5458A, C5468T, A5474G, A5596G, A5653G, C5662T, A5674G, C5713T, T5714C and C5980T~~C5059T, C5060T, G5074A, A5359G, T5401A, G5452A, G5458A, C5468T, A5474G, A5596G, A5653G, C5662T, A5674G, C5713T, T5714C and C5980T~~.

Claim 110. (Canceled)

111. (Currently Amended) The method of claim 106 wherein said at least one mutation is A5653GA method according to claim 106, comprising determining a decrease in the expression of mutant plexin B1 in the presence of said test compound.

Claims 112-114. (Canceled)

115. (new) The method of claim 106 wherein said plexinB1 nucleic acid comprises the plexinB1 coding sequence of AB007867.1 (SEQ ID NO:112) with a mutation A5653G.

116. (new) The method of claim 106 wherein said at least one mutation is T5059C or C5060T.

117. (new) The method of claim 106 wherein said putative agent is an anti-breast cancer putative agent and said at least one mutation is G5452A or G5458A and a reduction in expression of the plexinB1 nucleic acid in the cell or cell lysate in the presence of the test compound as compared with expression of the plexinB1 nucleic acid in the cell or the cell lysate in the absence of the test compound identifies the test compound as a putative anti-breast cancer agent.

WILLIAMSON ET AL  
Appl. No. 10/536,804  
Atty. Ref.: 620-373  
Amendment After Final Rejection  
December 21, 2009

118. (new) The method of claim 106 wherein said putative agent is an anti-prostate cancer putative agent and said at least one mutation is A5653G and a reduction in expression of the plexinB1 nucleic acid in the cell or cell lysate in the presence of the test compound as compared with expression of a of the plexinB1 nucleic acid in the cell or the cell lysate in the absence of the test compound identifies the test compound as a putative anti-prostate cancer agent.